Editorial Comment to Regional and facility disparities in androgen deprivation therapy for prostate cancer from a multi-institutional Japan-wide database.

Szczegóły
Comments

Tytuł:: Editorial Comment to Regional and facility disparities in androgen deprivation therapy for prostate cancer from a multi-institutional Japan-wide database.
Autorzy:: Hatakeyama S; Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan.
Ohyama C; Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan.
Źródło:: International journal of urology : official journal of the Japanese Urological Association [Int J Urol] 2021 May; Vol. 28 (5), pp. 591-592. Date of Electronic Publication: 2021 Mar 04.
Typ publikacji:: Editorial; Comment
Język:: English
Imprint Name(s):: Publication: Carlton South, Vic. : Blackwell Science Asia
Original Publication: Tokyo ; New York : Churchill Livingstone, c1994-
MeSH Terms:: Prostatic Neoplasms*/drug therapy
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Androgen Antagonists/adverse effects ; Androgens ; Antineoplastic Agents, Hormonal/therapeutic use ; Humans ; Japan/epidemiology ; Male
References:: Baade PD, Yu XQ, Smith DP, Dunn J, Chambers SK. Geographic disparities in prostate cancer outcomes-review of international patterns. Asian Pac. J. Cancer Prev. 2015; 16: 1259-75.
Shiota M, Sumikawa R, Onozawa M et al. Regional and facility disparities in androgen deprivation therapy for prostate cancer from a multi-institutional Japan-wide database. Int. J. Urol. 2021; 28: 584-91.
Hamaya T, Hatakeyama S, Momota M et al. Association between the baseline frailty and quality of life in patients with prostate cancer (FRAQ-PC study). Int. J. Clin. Oncol. 2021; 26: 199-206.
Momota M, Hatakeyama S, Soma O et al. Geriatric 8 screening of frailty in patients with prostate cancer. Int. J. Urol. 2020; 27: 642-8.
Kodama H, Hatakeyama S, Momota M et al. Effect of frailty and comorbidity on surgical contraindication in patients with localized prostate cancer (FRART-PC Study). Urol. Oncol. 2021; 39: 191.e1-191.e8.
Substance Nomenclature:: 0 (Androgen Antagonists)
0 (Androgens)
0 (Antineoplastic Agents, Hormonal)
Entry Date(s):: Date Created: 20210304 Date Completed: 20210514 Latest Revision: 20210514
Update Code:: 20240105
DOI:: 10.1111/iju.14539
PMID:: 33663016
: Opinia redakcyjna

Pełny tekst

Comment on: Int J Urol. 2021 May;28(5):584-591. (PMID: 33629386)

Informacja